Last edition
News about "Dr. Sharvil Patel"
Zydus Lifesciences Reports 22 Percent Revenue Growth in Q1 FY27, Advances Innovation Pipeline
Zydus Lifesciences began FY27 with strong double-digit growth, driven by robust performance across India and international formulations, alongside continued progress in manufacturing quality and biosimilar innovation.
Dr. Sharvil Patel | 12/08/2026 | By News Bureau
Zydus Wins US FDA Approval for Generic Indocyanine Green Injection
Zydus has received US Food and Drug Administration (FDA) approval for generic Indocyanine Green Injection, expanding its injectable imaging portfolio and functional dyes business.
Dr. Sharvil Patel | 06/08/2026 | By News Bureau | 118
US FDA Grants Priority Review to Zydus Therapeutics' Saroglitazar for Primary Biliary Cholangitis
Zydus Therapeutics has received US FDA Priority Review (PR) for its New Drug Application (NDA) for saroglitazar in the treatment of Primary Biliary Cholangitis (PBC), supported by phase 3 EPICS-III trial results demonstrating significant biochemical response, with detailed data to be presented at the EASL Congress 2026.
Dr. Sharvil Patel | 29/05/2026 | By News Bureau | 182
Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
Dr Sharvil Patel | 18/03/2026 | By News Bureau | 343
Zydus Partners with Bioeq for US Commercialisation of Lucentis Biosimilar
Zydus has entered into a partnership with Bioeq to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market. Under the agreement, Bioeq will handle development, manufacturing, regulatory approval and product supply, while Zydus will oversee US commercialisation.
Dr Sharvil Patel | 24/12/2025 | By News Bureau | 206
USFDA Grants ODD to Zydus' Desidustat for Beta-Thalassemia Treatment
Desidustat, a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), has received Orphan Drug Designation (ODD) from the USFDA. The designation grants eligibility for up to seven years of marketing exclusivity upon approval and highlights Desidustat’s potential to boost haemoglobin and red blood cell production.
Dr Sharvil Patel | 06/11/2025 | By Dineshwori | 228
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
Dr. Sharvil Patel | 04/10/2025 | By Dineshwori | 263
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities.
Dr. Sharvil Patel | 17/04/2025 | By Abha | 582
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy